Page 912«..1020..911912913914..920930..»

Category Archives: Transhuman News

The Impact of Air Pollution on Eczema – HealthCentral.com

Posted: June 11, 2021 at 12:16 pm

Exposure to toxins like wildfire smoke can leave you vulnerable to skin irritation.

Getty Images

For 17 harrowing days in November 2018, the deadliest wildfire in the Californias history swept across the northern region of the state. Officially dubbed the Camp Fire (named after its origin point at Camp Creek Road in Butte County), the fire continued to spread for several weeks, capturing national attention. Scientists and environmental experts recognized it as a sign of the increasing impacts of climate change on the West Coast wildfire season: As global temperatures rise, Californias already fire-prone landscape becomes more susceptible to dangerous blazes with each passing year.

For locals, the Camp Fires effects have long outlasted that initial media frenzy. Three years later, and many Californians are still working to rebuild their homes and lives. But disasters like this permeate deeper than the immediate economic damagethey also have a long-term impact on human health. A new study in JAMA Dermatology has found that wildfire smoke may trigger and exacerbate eczema symptoms, even in people with no known history of chronic skin disease.

Researchers at the University of California San Francisco collected data from dermatology visits by 4,147 people who lived in San Francisco, approximately 175 miles from the source of the Camp Fire. During the weeks when wildfire-related air pollution was highest, they discovered a significant increase in doctors visits related to atopic dermatitis (a.k.a. eczema) or itch. It wasnt just people with pre-existing eczema who developed symptoms during the wildfire, but also people who had never reported these symptoms before.

These findings illustrate one of many ways that air pollution, worsened by climate change, can aggravate (or induce) skin barrier dysfunction. Generally, conversations about climate change policy, mitigation, and prevention havent considered the effects of air pollution from wildfires on skin health, says Raj Fadadu, environmental epigenetics graduate student researcher at University of California San Francisco (UCSF) and first author of this study. Perhaps these [skin] diseases should be discussed more when thinking about the many ways in which the changing climate impacts human health.

One of the challenges in studying eczema is that its an extremely complicated health condition, and the origin and risk factors vary from person to person. Eczema (or atopic dermatitis, as it is formally known) is believed to be caused by a combination of genetics and environmental factors, both of which can compound to make symptoms worse. For instance, someone might be born with an overactive immune system (genetics), which is then triggered by external irritants like cigarette smoke or household cleaners (environment), causing an eczema flare.

The skin is a wonderful barrierthats its function, explains Maria Wei, M.D., professor of dermatology at UCSF and co-author of the wildfire study. It is a barrier against physical entities, gases, liquids, infections, and temperature [changes]. But it does have its limits, and there are ways for components of pollution to breach that barrierespecially when the skin barrier is already in a compromised state.

Exposure to pollutants contributes to eczema in several ways: oxidative stress, skin barrier dysfunction, immune stimulation, and exacerbation of itching and scratching. And different types of pollutioncar exhaust, construction zones, cigarette smokelikely have somewhat different impacts on the skin. But heres what we know: They all seem to have a very strong pro-oxidative effect, explains Raj Chovatiya, M.D., a dermatologist with Northwestern Medicine in Chicago.

These pollutants cause damage to the skin and deplete its natural antioxidant mechanisms. In addition, Dr. Chovatiya says, they can mess around with the normal skin microbiome, changing the balance of healthy cells that keeps your skin barrier strong and protective against infection. All of this, combined with the stimulation of your bodys immune response, contributes to skin irritation and eczema symptoms, and it may even trigger new symptoms in people with underlying skin sensitivity.

We know that chemical-based cleaning products (especially those with harsh ingredients or fragrances) can provoke eczema symptoms, so it makes sense that outdoor pollutants would be able to do this, too. But one major challenge researchers face is trying to sort out the specific impacts of air pollution on skin health. This is a very difficult kind of study to do in isolation, Dr. Chovatiya notes.

After all, its not like you can pick out individual air pollutants and expose people to them in a laboratory setting. We know there are a lot of different environmental factors that influence eczema, he says. Even aside from pollution, youre talking about UV light, precipitation, humidity, temperature, and other environmental factors.

So, what we see in the research is more of a case for correlation, not causationtheres a link between eczema and air pollution, but its not clear exactly how strong that link is or who is most at risk. One review in Clinical Reviews in Allergy & Immunology examined the effects of man-made outdoor pollutants like vehicle exhaust, tobacco smoke, and particulate matter on atopic dermatitis. The authors found strong evidence of a connection but emphasized the need for further research to better understand the specifics.

A 2019 literature review in the British Journal of Dermatology noted that while air pollutants pose a multifaceted threat to atopic dermatitis, the specific mechanism through which this happens is not totally clear. Similarly, this wildfire study revealed an association between wildfire pollution exposure and eczema symptoms, but the authors were not able to definitively name it as the primary cause.

Still, Dr. Chovatiya notes, the growing research on this topic is becoming more and more compelling. With the wildfire study, we have yet another piece of evidence to suggest that in addition to having negative impacts on the global environment, [air pollution] actually has a negative impact on health, he says. And targeting air pollution may be one way to slow the increase in eczema cases across the world.

The estimated prevalence of eczema has more than doubled in the past 30 years, especially in urban areas and industrialized countries. The rising prevalence of atopic dermatitis in industrialized countries globally is coincident with urbanization, industrialization, and consideration of the impact of air pollution on the development and course of atopic dermatitis, says Lawrence Eichenfield, M.D., professor of dermatology and pediatrics at UC San Diego School of Medicine and chair of the National Eczema Associations Scientific and Medical Advisory Council.

Air pollution is on the decline in some affluent countries, including the United States, yet 55% of the worlds population (mostly those in mid- to low-income countries) are being exposed to increasing levels of air pollution year after year. And although the air quality is improving here, its still far from where it needs to be: the Environmental Protection Agency (EPA) estimates that 97 million Americans lived in counties with pollution levels exceeding national air quality standards in 2020.

Both short term and long-term exposure to pollutants may exacerbate symptoms of atopic dermatitis, Dr. Eichenfield notes. This could be a key factor to help explain the vast upswing in atopic dermatitis diagnoses, especially in highly industrialized places with minimal environmental regulations.

So, whats next, and how do we begin to solve this global issue? Dr. Chovatiya hopes that future research will help distinguish the causes of eczema on a more individualized levelincluding the way that air pollution may damage the skin. Maybe air pollution doesnt matter to every single person with eczema, he considers. Who is going to be that person who is most affected by a forest fire, a high industrial area, or a construction site? This information would allow doctors to help patients craft a treatment plan that targets their specific needs.

For now, people with eczema can continue to stick to the generalized prevention guidance: avoid exposure to harsh chemicals, allergens, and fragrances. Being aware of pollution levels on a day-to-day basis is important, too, Dr. Eichenfield suggests, and minimizing outside time during bad pollution days is a reasonable strategy.

If youre hoping to broaden your impact and get involved in advocacy work, environmental groups like Earthjustice and the American Lung Association have clean air campaigns with opportunities for volunteers.

This conversation will remain relevant as we continue to see the impacts of environmental devastation caused by climate change. Fadudu hopes that the UCSF wildfire study can add one more piece to the puzzle of understanding climate change and public health. Not only can there be greater public health skin-related education for communities affected by wildfires, he says, but we can also use these results to show that wildfire smoke and air pollution affect peoples and communities skin health, which can impact quality of life. We all deserve access to clean natural spaces, for ourselves, our children, and the generations ahead.

Meet Our Writer

Sarah Ellis is a wellness and culture writer who covers everything from contraceptive access to chronic health conditions to fitness trends. She is originally from Nashville, Tennessee and currently resides in NYC. She has written for Elite Daily, Greatist, mindbodygreen and others. When shes not writing, Sarah loves distance running, vegan food, and getting the most out of her library card.

Original post:
The Impact of Air Pollution on Eczema - HealthCentral.com

Posted in Eczema | Comments Off on The Impact of Air Pollution on Eczema – HealthCentral.com

Incyte the latest to fall victim to JAK scrutiny as FDA pushes back Jakafi review in GVHD – FiercePharma

Posted: at 12:16 pm

The entire JAK inhibitor family of medicines isfeeling the ripple effects from a safety signal flagged for Pfizers Xeljanz. Now, the first marketed drug in the class is encounteringincreased scrutiny from the FDA.

The FDA has pushed back a decision for Incytes application for Jakafi in steroid-refractory chronic graft-versus-host disease (GVHD) by three months, the company said Tuesday. The new target action date isSept. 22.

The delay came after Incyte submitted additional data in response to a recent request by the agency. The FDA views the update as a major amendment to the previous package, so it now needs more time to review it, the drugmaker said.

Despite the setback, RBC Capital Markets analyst Brian Abrahams still believes Jakafi will eventually get its approval. Feedback from experts has been positive,with physicians noting limited alternatives and clear signs of efficacy for the drug, he wrote in a Wednesday note to clients. He projects the indication could get Jakafi over $300 million in U.S. peak sales.

Jakafi is only thelatest in the JAK drug class to face an FDA delay. Previously, the FDApostponed its verdict on Eli Lillys Incyte-partnered Olumiant and Pfizers investigational abrocitinib in moderate-to-severe atopic dermatitis. The agency also held up Xeljanzs filing in ankylosing spondylitis by three months. Before that, the agencydelayed two AbbVie filings for Rinvoq in eczema and psoriatic arthritis.

The extra hurdles stemmed from a safety problem observed in a post-marketing trial of Xeljanz in rheumatoid arthritis. The study linked an increased risk of dangerous heart-related side effects to the Pfizer JAK inhibitor compared with traditional TNF blockers in patients who were at least 50 years old withat least one existing cardiovascular risk factor.

RELATED:More relief for Dupixent as FDA pushes back Lilly, Pfizer eczema decisions on safety concerns

Jakafi was the first JAK inhibitor to reach the market with an FDA go-ahead for the bone marrow disease myelofibrosis in late 2011. The drug has been allowed in patients with steroid-refractory acute GVHD since May 2019.

The company's latest application in chronic GVHD comes off positive results from the phase 3 REACH3 trial. At week 24, the drug triggered a response in 49.7% ofpatients. For patients on best available treatments, 25.6% responded.

We remain confident in the data from the REACH3 trial supporting our sNDA submission for [Jakafi] and look forward to continued dialogue with the FDA throughout the remainder of the review process, Incytes chief medical officer, Steven Stein, M.D., said in a statement.

RELATED:ASH: Incyte, Novartis eye Jakafi approval after chronic graft vs. host win

Currently, Jakafi is given at different strengths twice daily. Incyte is evaluating a once-daily formulation with a potential approval expected by the end of 2022.

In a more important regulatory decision for Incyte, the company is also awaiting a verdict for a cream product with the same ruxolitinib active ingredient as used in the oral Jakafi for the treatment of atopic dermatitis. It used a priority review voucher for that application to secure an early decision date thats scheduled for June 21.

An Incyte spokesperson confirmed that the application for the topical drug remains under review at the FDA, though RBCs Abrahams said he now seesincrementally higher risk for a clean label.Last month, when asked about the increased JAK scrutiny at the FDA, Sten said the company is very comfortable where we are with the review.

Editor's Note: The story has been updated with analysisfrom RBC Capital Markets and a response from Incyte.

Read the original post:
Incyte the latest to fall victim to JAK scrutiny as FDA pushes back Jakafi review in GVHD - FiercePharma

Posted in Eczema | Comments Off on Incyte the latest to fall victim to JAK scrutiny as FDA pushes back Jakafi review in GVHD – FiercePharma

Kyowa Kirin’s San Diego lab just helped the pharma company make $400M on a deal for an eczema drug with Amgen – The San Diego Union-Tribune

Posted: at 12:16 pm

Japanese pharma giant Kyowa Kirin is set to receive $400 million in a deal that wouldnt have happened without the companys San Diego lab.

The company recently announced a partnership with Amgen to develop a drug against eczema, a skin condition that can leave painful and itchy rashes across your hands, feet and behind your knees, among other places. Those rashes break out when irritants and allergens pass through the outermost layer of skin, triggering inflammation.

Kyowa Kirins experimental treatment, developed by scientists at its La Jolla lab, targets immune cells responsible for these inflammatory signals. The drug uses an antibody, a Y-shaped protein, to target T cells, immune cells that normally play a key role in fighting off microbes but can also trigger friendly fire against the bodys own tissues. The small arms of that Y latch onto the surface of activated T cells, while scientists modified the other end to efficiently trigger other immune cells to kill T cells coated in the antibody.

In February, Kyowa Kirin reported that the drug, KHK4083, significantly reduced the size and severity of eczema rashes without causing serious side effects in a 274-person study.

If those results hold up in larger follow-up studies, Kyowa Kirin could pull in another $850 million from Amgen, plus future royalties on sales. More importantly, says Andrew McKnight, director of the companys La Jolla site, the drug could benefit up to 25 to 30 million patients across the U.S., Japan and Europe, regions where Kyowa Kirin and Amgen see the greatest market potential.

This opens up a new paradigm, a new therapy for those patients, he said.

Its just the latest example of the work done by his team of 42 scientists. The local lab is the only research facility Kyowa Kirin has outside of Japan, and its roots in San Diego site date to 1988 back when it was called Gemini Science.

During that time, the lab has worked closely with the La Jolla Institute of Immunology, founded around the same time. Kyowa Kirin helps fund the nonprofit research organizations annual budget, according to McKnight, and the company often follows up on promising initial findings from the institutes scientists. Its a long-running partnership that has led to an antibody treatment being developed against Crohns disease and now against COVID-19, too.

The local research lab has also developed its own drugs internally, including Crysvita, an antibody that helps treat patients with a genetic condition that leads to low phosphate levels in their blood, which can result in weak, soft bones.

The FDA approved Crysvita in 2018, and the drug was approved in Japan in 2019. During the first three months of 2021, Kyowa Kirin earned $162 million in sales from Crysvita, easily exceeding revenue from any of its other products, according to the companys financial reports.

Read more here:
Kyowa Kirin's San Diego lab just helped the pharma company make $400M on a deal for an eczema drug with Amgen - The San Diego Union-Tribune

Posted in Eczema | Comments Off on Kyowa Kirin’s San Diego lab just helped the pharma company make $400M on a deal for an eczema drug with Amgen – The San Diego Union-Tribune

Womans excruciating reaction to steroid cream withdrawal after eczema treatment – NEWS.com.au

Posted: at 12:16 pm

A woman has warned eczema sufferers against overuse of steroid medication, sharing her painful journey through Topical Steroid Withdrawal, which left her with an excruciating lizard-like rash all over her face and body.

Megan Crome, a 25-year-old digital marketing assistant from London described showering as like having acid poured over her skin at the height of her reaction, revealing the horrendous experience absolutely shattered her quality of life.

Megan, who had to move back in with her parents for the three-month withdrawal period, was diagnosed with eczema when she was six-years-old, but her condition worsened through her final year of school.

RELATED: I wanted to die: Rash ruins womans life

After years of navigating various steroid treatments for her condition, she developed a resistance known as Topical Steroid Addiction (TSA) which left her with red and swollen skin.

When she stopped using the medication, the pain only worsened, making it difficult to do everyday tasks and prompting her take to time off from her job.

I was suffering every second of the day for three months straight. I always had pain somewhere and couldnt make my own meals, go out or do simple tasks due to this, she said.

I didnt recognise myself in the mirror for months and my whole face was just damaged skin that was inflamed and falling off it was absolute hell and thinking back on it now, it is very upsetting as it was quite traumatic, she admitted.

RELATED: Awful cause of mums red face

The traumatic ordeal had a massive impact on her mental health, she revealed.

TSW absolutely shattered my quality of life. I had to take time off work, stop seeing my friends and move back home. All I could do was lay in bed and try to find a position that was somewhat comfortable without any of my open wounds touching the bed.

My friends have been very understanding, but I have missed out on a lot of time with them and I do worry about how this will affect my relationship with them going forward.

Describing her long-term struggle with eczema, Megan said she was initially prescribed hydrocortisone, followed by a stronger cream called betnovate.

When the condition worsened in her teenage years, she was prescribed more steroid creams including elocon and protopic, neither of which had much of an effect.

Megan remembers eventually developing red sleeves, a common symptom of Topical Steroid Addiction (TSA), which left her skin swollen and arms hot to the touch.

Her skin began to weep and scab over due to her whole body being scratched red raw, where her face was engulfed in thick scabs which were continuously prone to infections.

I believe the steroids given to me absolutely exacerbated my skin problems without me even realising, Megan said, going on to add she sought advice from online support groups which told her to quit cold turkey but warned of the difficult journey ahead.

The short but brutal route meant she stopped using all moisturisers and creams to push the body to create its own natural oils, noticing the reaction almost instantly.

I had burning, hot skin, but felt freezing cold inside, extreme flaking which made me feel like a lizard shedding its skin, as well as insomnia where I wasnt able to lay still or relax for any longer than five seconds, she said.

Concluding her ordeal, she revealed she is speaking out in the hopes of raising awareness for others.

I feel so strongly that doctors need to be educated on the effects of steroids and stop handing them out for anything and everything.

Megan now helps her condition by eating healthily and has cut out dairy, wheat, and gluten, as well as taking vitamins and fish oil everyday.

Original post:
Womans excruciating reaction to steroid cream withdrawal after eczema treatment - NEWS.com.au

Posted in Eczema | Comments Off on Womans excruciating reaction to steroid cream withdrawal after eczema treatment – NEWS.com.au

Mask related acne (maskne) and other facial dermatoses – The BMJ

Posted: at 12:16 pm

The covid-19 pandemic has led to a marked increase in the use of personal protective equipment (PPE) both in and out of healthcare settings. The term maskne has become increasingly popular during the pandemic, particularly in the media, where it is used to describe several facial dermatoses. Individuals often buy expensive but potentially ineffective treatments for these conditions.

In this practice pointer we summarise the most common causes of facial eruptions associated with wearing facial PPE, and highlight the key areas to cover when assessing someone with new or worsening pre-existing facial dermatoses that they attribute to the use of facial PPE.

Facial PPE in this article includes full face shields, visors, safety spectacles, surgical masks (fluid resistant surgical mask, FRSM type IIR), and respirator masks (eg, FFP3, FFP2, and N95).1

Facial dermatoses related to PPE have been well described, but data about their prevalence are limited, and often a descriptive terminology is used rather than specific diagnoses. Based on the limited available evidence, mask related acne and irritant contact dermatitis are the most common facial dermatoses associated with mask wearing.2345

During the covid-19 pandemic, a prospective cross sectional study of 833 medical school staff in Thailand, including healthcare and non-healthcare workers, showed a self-reported prevalence of 54% adverse skin reactions to surgical and cloth masks.6

Typically, a patient presents with new onset facial eruption, or exacerbation of a pre-existing dermatosis that is most pronounced in the area covered by the mask. Ideally, such an assessment would take place in person, but video consultation provides an acceptable alternative.

Relevant history and family history of skin disease and a comprehensive drug history that includes prescribed, over-the-counter, and complementary medicines

Temporal relationship with mask wearingestablish if periods without mask wearing alleviate or improve the problem, eg, allergic contact dermatitis should improve with a period of no mask wearing, while acne, once established, may not respond so readily

Symptoms of itch, soreness, and appearance of pustules or papules

Duration of PPE exposure each day

Ask if mask breaks (periods of time when facial PPE is removed entirely) are allowed or taken

Assess the impact on the patients mood, work, and social life to assess severity and decide further management. The effect of PPE related dermatoses on the life quality of healthcare workers can be substantial3

Examination should focus on the morphology of the eruption, the distribution, and whether it is present at sites other than the face.

Each condition described below may appear de novo or be exacerbated by wearing facial PPE. Exacerbation tends to result from the development of a warm, moist, occlusive environment around the face, particularly during mask use. Added to this is the frictional effect of the material held in place with elastic.

General measures to prevent PPE related facial dermatoses are outlined in the box and are advised in the treatment of all conditions listed below. Additional standard medical treatment for each dermatosis is discussed separately. When post-inflammatory hyperpigmentation or scarring occurs, a more aggressive treatment approach is required to prevent irreversible skin changes. Referral to specialist care is warranted at this stage if no improvement occurs.

Irritant contact dermatitis (ICD) is the most common occupational and mask related dermatosis.3 ICD is a form of exogenous eczema caused by direct physical or chemical injury. Pressure ICD related to facial masks is commonly described4 over the cheeks and nasal bridge.35 It is associated with prolonged mask wearing (>6 hours) and its severity depends on the irritant and chronicity of exposure.3 Presentation ranges from a discrete, dry, scaly patch to oedema and vesicles, erosions, and ulceration.35 People with atopic dermatitis, who already have a defective skin barrier, are particularly at risk of developing ICD.7

Enabling restoration of the skin barrier is key to treating ICD, and regular mask breaks (every hour for respirators) is one way to do this.8 For broken skin, a silicon backed dressing such as Mepilex Border Lite can be applied to protect the skin and ensures that the mask seal remains intact.9

Allergic contact dermatitis (ACD) (fig 1) is a delayed type IV hypersensitivity reaction to an external allergen, and is much less common than ICD.910 Typically, it occurs after exposure to preservatives such as formaldehyde11 and dibromodicyanobutane,12 but thiuram, a rubber accelerator found in the elastic straps on surgical masks,13 is also a recognised allergen. Metal wires are used to mould the mask to the face; nickel and cobalt have both been reported as causes of facial ACD.14

Allergic contact dermatitis

ICD and ACD can be clinically indistinguishable. Both usually manifest as localised dermatitis but well demarcated areas of inflammation and redness are more suggestive of ACD, while a more diffuse pattern is more commonly seen in ICD. Treatment involves a short course of a mild to moderate potency corticosteroid, such as hydrocortisone 1% ointment. Avoiding allergens prevents further episodes, and therefore identification of causative agents is key. This can be achieved by patch testing, indicated where well demarcated areas are seen clinically and in cases of severe disease.

Atopic eczema is a very common dermatitis that affects up to 20-30% of children and 2-10% of adults.15

Wearing a mask may have an irritant effect on the more delicate facial skin of a patient with eczema, plus the occlusive, moist environment favoured by mask wearing may have a deleterious effect on the skin, favouring the worsening of eczema.

This dermatosis (fig 2) affects approximately 1-3% of the adult population and usually starts in young adult life.16 On examination, a dermatitis with greasy yellow scale predominantly affecting the scalp, eyebrows, glabellar, and nasolabial folds is common. Management involves regular antifungals such as ketoconazole 2% shampoo and/or short courses of mild topical corticosteroids such as hydrocortisone 1% ointment.17 As with atopic eczema, the warm, moist, occlusive environment created by mask wearing may predispose to development of seborrhoeic dermatitis.

Periorificial dermatitis consists of a patchy erythema with tiny papulopustules, affecting the periocular and perioral skin of young women (with sparing of the vermilion border). It can be idiopathic, or is caused by the use of cosmetics or topical corticosteroids directly or indirectly (via fingers that are applying the agent elsewhere). Mask wearing may predispose to the development of periorificial dermatitis for reasons similar to those listed for atopic and seborrhoeic dermatitis. Management involves stopping the implicated cream and simplifying the skin care regimen. Topical antibiotics such as erythromycin will suffice for milder cases but often a four week course of a tetracycline, such as lymecycline 408 mg once daily, is needed.18

Both pressure and contact urticaria (fig 3) are uncommon complications of PPE.1119 Pressure urticaria is caused by the downward pressure of the mask and is characterised by the formation of wheals, immediately or delayed (4-6 hours), after a pressure stimulus. A well fitted mask that is not over tight is recommended, or alternatively a change in PPE.19

Contact urticaria is an immediate reaction to an offending allergen such as latex or formaldehyde. It typically resolves within 24 hours of removal of the contact trigger. Regular non-sedating H1 antihistamines such as loratadine are the mainstay of treatment for inducible urticaria.20

Acne vulgaris (fig 4) is a chronic inflammatory disease of the pilosebaceous unit. PPE related acne, which may be considered a subtype of acne mechanica, occurs in people with a previous history of acne vulgaris as well as in those previously unaffected. It has been associated with surgical masks and N95 respirators.2321

The pathogenesis of PPE related acne is thought to be threefold:

Creation of a humid microclimate inside the mask

Mucosa can be colonised by bacteria which could increase bacterial load on the surrounding skin

Friction effect of a close fitting mask can damage the follicular ostia causing chronic irritation, and this effect is worsened by heat and humidity.22

Retinoids such as adapalene cream alone or in combination with benzoyl peroxide cream once daily can be used for mild cases, with the addition of an oral tetracycline such as lymecycline 408 mg once daily for up to 12 weeks for moderate to severe cases.23

Rosacea (fig 5) typically affects adults aged 30-50 with fair skin.18 Commonly, patients present with facial erythema and telangiectasias of the convexities (chin, cheeks, nose, forehead). The classic area of distribution of rosacea overlaps with that covered by a mask when worn correctly. The chronicity and presence of telangiectasias usually help to distinguish rosacea from peri-orifical dermatitis. Rosacea can be induced or worsened by prolonged periods of mask wearing. Medical treatment includes topical agents such as ivermectin 1% cream once daily for mild cases. An oral tetracycline such as moderate release doxycycline 40 mg once daily for 8-12 weeks can be added for moderate to severe cases.24

Folliculitis (fig 6) on the face is more common in men because of its association with facial hair. Occlusive folliculitis, bacterial folliculitis, and pseudofolliculitis barbae (caused by ingrowing hairs) have clinically similar presentations with papules, pustules, and more rarely nodules. A swab can exclude bacterial infection. Gentle daily cleansing with a soap-free cleanser, gentle exfoliation (to release ingrown hairs), and replacing dry shaving with wet shaving can all be helpful. Antibiotic treatment is indicated where bacteria are isolated; in purely inflammatory (sterile) cases, a combination steroid/antimicrobial cream can be used.25

Cleanse skin26 with a gentle soap-free cleanser

Apply a light emollient at least 30 minutes before applying facial PPE26

Apply a silicon based barrier tapeeg, siltape (Advancis)to nasal bridge and cheeks49

Wipe skin under PPE with a silicon based barrier wipe to provide a film, protecting the skin from the harmful microenvironment26

Take time to fit the mask and ensure it is not over tight26

Take regular breaks from the mask (every one hour for respirators) to relieve the pressure and prevent moisture build up26

Stay well hydrated26

Maintain oral hygiene (teeth brushing twice daily and daily interdental flossing/brushing)27

Consider referral to secondary care in cases of severe, debilitating disease, or if the condition fails to respond to the treatments described above. Also consider a routine referral if specialist investigations, such as skin prick testing and patch testing in cases of suspected contact allergy, are indicated.

Consider how a facial dermatosis affects the patients quality of life, work, and relationships

Reflect on whether you incorporate considerations of different Fitzpatrick skin types in your treatment decisions, given the higher risk of post-inflammatory dyspigmentation and/or scarring in darker skin types

Consider the occupational implications of the diagnosis and treatment for the patient, and discuss these as part of the consultation

Signpost patients to the British Association of Dermatologists website as a useful repository of good quality reliable patient information leaflets on skin conditions (https://www.bad.org.uk)

This article was reviewed by two healthcare workers who had experienced PPE related facial dermatoses and whose experience of receiving care informed the content of this article. Specifically, they advised on the content of the box General measures to prevent PPE related facial dermatoses.

We obtained evidence using a systematic search of Medline, Embase, and Pubmed. Searches were confined to those publications written in the English language. Search terms used were facial dermatoses and mask, facial dermatoses and PPE, acne and PPE, acne and mask, eczema and mask, allergic contact dermatitis and mask, FFP3 mask and skin, N95 mask and skin.

Read the original post:
Mask related acne (maskne) and other facial dermatoses - The BMJ

Posted in Eczema | Comments Off on Mask related acne (maskne) and other facial dermatoses – The BMJ

These Are My Favorite Things from Tatchas Summer Celebration – New York Magazine

Posted: at 12:16 pm

Photo-Illustration: Courtesy of retailer

Editors note: Our beauty writer Rio Viera-Newton first wrote a version of this post in October 2019, when Tatcha had a very rare sitewide sale. And starting today, Wednesday, June 9, Tatcha is having another (but still fairly rare) sitewide sale. This time, its called the Summer Celebration, and many of Rios favorites are 20 percent off with the code SUMMER21. So were republishing her post to help you shop the sale smartly. But dont dillydally: It ends on Friday, June 14.

Tatcha was one of the first high-end skin-care brands I fell in love with. During some of my most brutal skin phases, Tatcha products have single-handedly saved my complexion from bad breakouts, dullness, and dryness. They also have some of the best dewiness-inducing, radiance-boosting, pre-event skin care Ive ever used. What I love about Tatcha is that while the products are incredibly effective, theyre equally gentle you get results without harsh chemicals or skin irritation.

Of course, theres a downside: Tatchas goods are horrifyingly expensive. Their Indigo Cream may have made my dry, eczema-prone skin supple and soft last winter, but paying $85 to re-up became unsustainable. And while the Silk Primer rid me of my fear of primers (they usually make me break out, and this one decidedly did not), 0.7 ounces of it will cost you a shocking $52. Are you upset? Ready for some good news? Here it is: Tatcha is having a 20 percent sitewide Summer Celebration sale from now through June 14, if you use the code SUMMER21 at checkout. (Note that sets are excluded from the sale.) If youre overwhelmed or curious where to start, Im here to help. I created a list of all my favorite products from the Tatcha sale some you may recognize from previous articles, others are new friends.

This Dewy Skin Cream from Tatcha has quickly become on my all time favorite pre-makeup skin-prep heroes. After applying this cream, youll instantly notice that your skin looks plumper, brighter, and intensely nourished. I have super-temperamental, eczema-prone skin that loves to curse me with flakey dry patches as soon as the temperature drops below 70 degrees. This cream heals any of that and gives me the glowy skin base of my dreams. Plus, makeup glides over it like a dream. This is a must-have for all dewy-skin enthusiasts or makeup lovers.

One of my all-time favorite, pre-event staples is this Violet-C Vitamin C Radiance Mask. Just to get this out of the way: This mask is the most beautiful violet color, so taking photos in it is super-fun. But apart from the aesthetic delights of this product, it has awesome skin-brightening and skin-nourishing ingredients. This mask is packed with green tea, algae, and rice for anti-aging, skin-softening, and hydrating benefits, as well as two types of vitamin C (oil soluble and water soluble), so make sure your skin is getting that antioxidant protection and serious radiance boost.

As someone with super-dry, irritable skin, I love an essence. If you havent yet incorporated an essence into your routine, its a great supplementary step to ensure your skin is getting as much moisture and nourishment as it needs after exfoliating. This essence from Tatcha I tried a little while ago and fell in love with. Much like that of the dewy-skin cream, the ingredient list includes what Tatcha deems their holy trinity: green-tea extract, algae, and rice, which, when fermented, all have amazing plumping, softening, and hydrating effects. This is great for anyone who struggles with dryness, as it doubles the skins moisture intake.

This is one of the best nighttime moisturizers I have ever used. Its very rich, but it absorbs into the skin quickly and so doesnt leave you feeling greasy or sticky. The products blend of oatmeal and Japanese indigo is calming and reparative and has helped me calm redness from breakouts and eczema. For anyone with dry, acne-prone skin, this is a must-try.

When it comes to face mists, this one is the one to try.On rushed, no-makeup mornings, I sometimes use this as the only step in my routine: A few spritzes on clean skin provide nourishment and moisture and make my face look super-bright and dewy.On full-on glam makeup days, I use this as my final, makeup-setting step. It makes everything melt into my skin and gives a perfect, flawless finish.

I wrote a full-length review of this product, so if you want the nitty-gritty, read it. But very long story short: This is one of the only primers Im willing to use. Not only does this never, ever make me break out, it also keeps my makeup looking frighteningly fresh and flawless like Ive just applied it all day long.

If youre looking for a great everyday sunscreen, this one is definitely worth buying. It absorbs super quickly into the skin and doesnt leave a white cast. Plus, after you apply, makeup glides on super easily on top of it. It also has a slight matte-ifying effect on the skin, so it wont leave you looking greasy which I think we all can agree is unique for an SPF. The sunscreen is sold out in the full-size version, so we included the travel-size here.

This lip balm is not only the perfect gift (it has pretty gold flakes in it), its also really effective. Apparently Japanese female free divers have used camellia oil (the main product in this balm) for thousands of years to protect their skin and hair from the salty ocean water. I can see why: This super-thick and creamy lip balm does a truly incredible job at soothing and healing chapped lips. It is probably my second-favorite chapstick of all time, right after my beloved Bite Agave Lip Mask.

This is a physical not a chemical exfoliant. Though it is technically a scrub, it is incredibly gentle it contains rice bran and papa enzymes and transforms into a foam when you add water to it. Tatchas ethos is, essentially, that doing small things for your skin every day will give you the best results (instead of using super-intense chemical exfoliants, in other words). This product is the definition of that: Itll never make your skin red and dry, but it will make it noticeably smoother within just one use.

Actually good deals, smart shopping advice, and exclusive discounts.

The Strategist is designed to surface the most useful, expert recommendations for things to buy across the vast e-commerce landscape. Some of our latest conquests include the best acne treatments, rolling luggage, pillows for side sleepers, natural anxiety remedies, and bath towels. We update links when possible, but note that deals can expire and all prices are subject to change.

Every editorial product is independently selected. If you buy something through our links, New York may earn an affiliate commission.

See original here:
These Are My Favorite Things from Tatchas Summer Celebration - New York Magazine

Posted in Eczema | Comments Off on These Are My Favorite Things from Tatchas Summer Celebration – New York Magazine

Conversations That Matter: Talk GMO with a GMO scientist – Vancouver Sun

Posted: at 12:15 pm

Breadcrumb Trail Links

Humans have been tinkering with the genetics of food for millennia, but modern genetic engineering techniques have proven controversial

Author of the article:

Clustered regularly interspaced short palindromic repeats.

Otherwise known as CRISPR, it is a term many people know is associated with genetic engineering particularly of food. But, what exactly is genetic engineering?

The science of adjusting the genetic makeup of plants has been in process for thousands of years. From the time humans transitioned from hunter-gatherers to farmers, weve been tinkering with food. This plant has those characteristics and if we wed them to this one, will it grow better in this environment? Will it taste better? Will it be drought-resistant? Will it be disease tolerant? And so on.

By the middle of the last century, scientists were rapidly moving toward sequencing the genomes of everything, including people. Genetics now play a vitally important role in innovations in medicine, trees, food, etc.

Somewhere along the way, genetic engineering of food got a bad rap and, now, many people are openly campaigning against bioengineering of plants.

I wanted to ask someone who actually does this type of work, what they do, why they do it, and can we trust them and the foods they produce. Larry Gilbertson of Bayer Crop Sciences joined a Conversation That Matters about innovations in plant biotechnology.

Please become a Patreon subscriber and support the production of this program, with a $1 pledge here

Go here to see the original:
Conversations That Matter: Talk GMO with a GMO scientist - Vancouver Sun

Posted in Genetic Engineering | Comments Off on Conversations That Matter: Talk GMO with a GMO scientist – Vancouver Sun

The science behind GM crops – The Hindu

Posted: at 12:15 pm

More than 10% of the worlds crop land grow Genetically Modified crops or GM crops. Scientists around the world have been asserting that GM crops can solve the worlds hunger problem. Still concerns about health and environment prevail. What are GM crops and what are their merits and demerits? Lets find out...

As the name suggests, GM food involves the editing of genes of a crop in such a way that it incorporates beneficial traits from another crop or organism. This could mean changing the way the plant grows, or making it resistant to a particular disease. Food produced using the edited crop is called GM food. This is done using the tools of genetic engineering.

Let us assume that scientists want to produce wheat with high protein content and they decide to incorporate the high protein quality of beans into wheat. To make this possible, a specific sequence of DNA with protein-making trait is isolated from the bean (which is called the donor organism) and is inserted into the gene structure of wheat, in a laboratory process. The new gene or the transgene thus produced is transferred into the recipient cells (wheat cells). The cells are then grown in tissue culture where they develop into plants. The seeds produced by these plants will inherit the new DNA structure.

Traditional cultivation of these seeds will then be undertaken and we will have genetically modified wheat with high protein content. The trait can be anything. A DNA from a plant that has high resistance to pests can be introduced into another so that the second plant variety will have the pest-resistant trait. A DNA of blueberry could be inserted into that of a banana to get a blue banana. The exchange could be effected between two or more organisms. One can even introduce a gene of a fish into a plant. You dont believe it? Consider this fact. Genes from an Arctic fish were inserted into tomatoes to make it tolerant to frost. This tomato gained the moniker fish tomato. But it never reached the market.

GM crops are perceived to offer benefits to both producers and consumers. Some of them are listed below...

Genetic engineering can improve crop protection. Crops with better resistance to pest and diseases can be created. The use of herbicides and pesticides can be reduced or even eliminated.

Farmers can achieve high yield, and thereby get more income.

Nutritional content can be improved.

Shelf life of foods can be extended.

Food with better taste and texture can be achieved.

Crops can be engineered to withstand extreme weather

Genetically engineered foods often present unintended side effects. Genetic engineering is a new field, and long-term results are unclear. Very little testing has been done on GM food.

Some crops have been engineered to create their own toxins against pests. This may harm non-targets such as farm animals that ingest them. The toxins can also cause allergy and affect digestion in humans.

Further, GM crops are modified to include antibiotics to kill germs and pests. And when we eat them, these antibiotic markers will persist in our body and will render actual antibiotic medications less effective over a period of time, leading to superbug threats. This means illnesses will become more difficult to cure.

Besides health and environmental concerns, activists point to social and economic issues. They have voiced serious concern about multinational agribusiness companies taking over farming from the hands of small farmers. Dependence on GM seed companies could prove to be a financial burden for farmers.

Farmers are reluctant because they will have limited rights to retain and reuse seeds.

Their concern also includes finding a market that would accept GM food.

People in general are wary of GM crops as they are engineered in a lab and do not occur in Nature

Excerpt from:
The science behind GM crops - The Hindu

Posted in Genetic Engineering | Comments Off on The science behind GM crops – The Hindu

Researchers Improve Efficiency and Accessibility of CRISPR – Caltech

Posted: at 12:15 pm

One of the most powerful tools available to biologists these days is CRISPR-Cas9, a combination of specialized RNA and protein that acts like a molecular scalpel, allowing researchers to precisely slice and dice pieces of an organism's genetic code.

But even though CRISPR-Cas9 technology has offered an unprecedented level of control for those studying genetics and genetic engineering, there has been room for improvement. Now, a new technique developed at Caltech by biology graduate student Shashank "Sha" Gandhi in the lab of Marianne Bronner, Distinguished Professor of Biology and director of the Beckman Institute, is taking CRISPR-Cas9 accessibility to the next level.

In a paper appearing in the journal Development, Gandhi and members of Bronner's lab describe the new technique, which has been designed specifically to disable or remove genes from a genome. This is known as "knocking out" a gene.

Gene knockout is an important method for studying what genes do because researchers can compare the behavior of a cell that has a working gene to the behavior of a cell in which that gene has been disabled. CRISPR-Cas9 has already been used for this, usually alongside genetic material that encodes a fluorescent protein, which makes it easy to identify cells from which a gene has been removed; cells with a knocked-out gene will glow.

One drawback of the technique, however, is that each part of the payload that makes it workthe Cas9 protein, the guide RNA, and the code for the fluorescent proteinhave to be delivered separately using a technique called electroporation, which opens the membranes of cells by zapping them with electricity. This can result in some cells receiving only some of the pieces. Thus, a cell could receive the code for making fluorescent protein, but not end up with a knocked-out gene. Or a cell could end up with its targeted gene knocked out, but not have the code to make fluorescent protein. Either case makes it more challenging for researchers to study how the cells are behaving.

"The advent of CRISPR has allowed people like me and Sha to work on just about any organism," Bronner says. "The caveat is that not every cell gets the same cocktail."

Another, bigger problem, has been that these CRISPR-Cas9 combinations often did not work across species lines because of a component known as a U6 promotera DNA sequence that tells a cell's machinery when and where to start making the guide RNA from a plasmid, a short loop of DNA that can be easily introduced into cells. A promoter that works in a fruit fly's genome will not necessarily work in that of a mouse, for example.

"The problem with the U6 promoter is that every species has its own version, so if you're working on a new system, you might not have a U6 to use," says Gandhi.

The new tool developed by Gandhi and other researchers in Bronner's lab eliminates both problems. Whereas the old CRISPR-Cas9 delivered each part of their payload separately, the new tool packages them together on a single plasmid. Because the plasmid contains all three required parts, the problem of a cell receiving only one or two of them is eliminated. The team's design also bypasses the need for using a U6 promoter, thereby enabling CRISPR-Cas9-based editing across multiple species.

"If you use plasmids for your CRISPR-Cas9 knockout experiments in an organism, this is the best way so far," Gandhi says.

Gandhi says that there is a growing interest in the tool among other research teams.

"We've actually been getting requests from around the world from people who are interested in using these tools in their research," he says. "I think that it will take a little bit of time for the tool to really pick up, but we've already received a lot of requests."

Bronner adds that her lab is working with Niles Pierce, professor of applied and computational mathematics and bioengineering, to develop more elaborate implementations of the tool.

"We're working on making this tool conditional, so you could say 'I want to lose gene X when gene Y turns on,' and the results are looking really promising," she says.

The paper describing their work, titled, "A single-plasmid approach for genome editing coupled with long-term lineage analysis in chick embryos," appears in the April 1 issue of the journal Development. Co-authors are biology graduate student Weiyi Tang; senior postdoctoral scholar in biology and biological engineering; Michael L. Piacentino, senior postdoctoral scholar research associate in biology and biological engineering; former postdoctoral scholars Yuwei Li and Felipe M. Vieceli; graduate student Hugo A. Urrutia; and Jens B. Christensen from the University of Copenhagen.

Funding for the research was provided by the National Institutes of Health and the American Heart Association.

See the article here:
Researchers Improve Efficiency and Accessibility of CRISPR - Caltech

Posted in Genetic Engineering | Comments Off on Researchers Improve Efficiency and Accessibility of CRISPR – Caltech

Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder -…

Posted: at 12:15 pm

REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, today announced the expansion of its strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (Takeda) for the research and development of an additional gene therapy for a lysosomal storage disorder bringing the total number of programs under the agreement to four.

Under the terms of the original March 2020 agreement, Codexis leveraged its CodeEvolver protein engineering platform to generate novel gene sequences encoding enzyme variants that are tailored to enhance efficacy by increasing activity, stability, and cellular uptake. Takeda is combining these improved transgenes with its gene therapy capabilities to develop novel candidates for the treatment of rare genetic disorders.

We are thrilled to expand our collaboration with Takeda to advance novel gene therapies for the treatment of rare diseases. Over the past year, our CodeEvolver technology has generated novel genetic sequences that encode more efficacious enzymes for the potential treatment of Fabry and Pompe Diseases, as well as an undisclosed blood factor deficiency. Codexis and Takeda are excited about the prospect for each of these improved sequences to enable differentiated gene therapies for patients with rare genetic diseases, stated John Nicols, Codexis President and CEO.

Gjalt Huisman, Codexis Senior Vice-President, Biotherapeutics added, Within a year of embarking on our collaboration, the Codexis and Takeda research teams have made tremendous progress in generating and evaluating engineered gene sequences for the three separate therapeutic indications. We are proud that based on the results to date Takeda has exercised its option to initiate a fourth program.

Terms of AgreementUnder the terms of the original agreement, the parties began collaborative work on three initial programs. Takeda had the contractual option to expand the collaboration into a fourth program. Codexis is responsible for the creation of novel enzyme sequences for advancement as gene therapies into pre-clinical development. Takeda is responsible for the pre-clinical and clinical development and commercialization of gene therapy products resulting from the collaboration programs. Subject to the terms of the agreement, Codexis is eligible to receive an upfront payment, reimbursement for research and development fees, development and commercial milestone payments, and low- to mid-single digit percentage royalties on sales of any commercial product developed through programs initiated under the agreement.

About Codexis, Inc.Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics. The Companys unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit http://www.codexis.com.

Forward-Looking StatementsTo the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including Codexis expectations regarding the prospects for the development and future commercialization by Takeda of novel gene therapies for specified target indications. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis dependence on its licensees and collaborators; the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable; results of preclinical studies and early clinical trials of product candidates may not be predictive of results of later studies or trials; even if we or our collaborators obtain regulatory approval for any products that are developed during a collaboration, such products will remain subject to ongoing regulatory requirements, which may result in significant additional expense; and there may be potential adverse effects to Codexis business if our collaborators products are not received well in the markets. Additional information about factors that could materially affect actual results can be found in Codexis Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2021 and in Codexis Quarterly Report on Form 10-Q filed with the SEC on May 7, 2021, including under the caption Risk Factors and in Codexis other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Contact:Argot PartnersStephanie Marks/Carrie McKimCodexis@argotpartners.com(212) 600-1902

See the rest here:
Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder -...

Posted in Genetic Engineering | Comments Off on Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder -…

Page 912«..1020..911912913914..920930..»